Cargando…
Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors
Inflammatory Breast Cancer (IBC) is an aggressive form of invasive breast cancer, highly metastatic, representing 2–4% of all breast cancer cases in the United States. Despite its rare nature, IBC is responsible for 7–10% of all breast cancer deaths, with a 5-year survival rate of 40%. Thus, targete...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395282/ https://www.ncbi.nlm.nih.gov/pubmed/34445288 http://dx.doi.org/10.3390/ijms22168581 |
_version_ | 1783744137170780160 |
---|---|
author | Santiago-Sánchez, Ginette S. Noriega-Rivera, Ricardo Hernández-O’Farrill, Eliud Valiyeva, Fatma Quiñones-Diaz, Blanca Villodre, Emilly S. Debeb, Bisrat G. Rosado-Albacarys, Andrea Vivas-Mejía, Pablo E. |
author_facet | Santiago-Sánchez, Ginette S. Noriega-Rivera, Ricardo Hernández-O’Farrill, Eliud Valiyeva, Fatma Quiñones-Diaz, Blanca Villodre, Emilly S. Debeb, Bisrat G. Rosado-Albacarys, Andrea Vivas-Mejía, Pablo E. |
author_sort | Santiago-Sánchez, Ginette S. |
collection | PubMed |
description | Inflammatory Breast Cancer (IBC) is an aggressive form of invasive breast cancer, highly metastatic, representing 2–4% of all breast cancer cases in the United States. Despite its rare nature, IBC is responsible for 7–10% of all breast cancer deaths, with a 5-year survival rate of 40%. Thus, targeted and effective therapies against IBC are needed. Here, we proposed Lipocalin-2 (LCN2)—a secreted glycoprotein aberrantly abundant in different cancers—as a plausible target for IBC. In immunoblotting, we observed higher LCN2 protein levels in IBC cells than non-IBC cells, where the LCN2 levels were almost undetectable. We assessed the biological effects of targeting LCN2 in IBC cells with small interference RNAs (siRNAs) and small molecule inhibitors. siRNA-mediated LCN2 silencing in IBC cells significantly reduced cell proliferation, viability, migration, and invasion. Furthermore, LCN2 silencing promoted apoptosis and arrested the cell cycle progression in the G0/G1 to S phase transition. We used in silico analysis with a library of 25,000 compounds to identify potential LCN2 inhibitors, and four out of sixteen selected compounds significantly decreased cell proliferation, cell viability, and the AKT phosphorylation levels in SUM149 cells. Moreover, ectopically expressing LCN2 MCF7 cells, treated with two potential LCN2 inhibitors (ZINC00784494 and ZINC00640089) showed a significant decrease in cell proliferation. Our findings suggest LCN2 as a promising target for IBC treatment using siRNA and small molecule inhibitors. |
format | Online Article Text |
id | pubmed-8395282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83952822021-08-28 Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors Santiago-Sánchez, Ginette S. Noriega-Rivera, Ricardo Hernández-O’Farrill, Eliud Valiyeva, Fatma Quiñones-Diaz, Blanca Villodre, Emilly S. Debeb, Bisrat G. Rosado-Albacarys, Andrea Vivas-Mejía, Pablo E. Int J Mol Sci Article Inflammatory Breast Cancer (IBC) is an aggressive form of invasive breast cancer, highly metastatic, representing 2–4% of all breast cancer cases in the United States. Despite its rare nature, IBC is responsible for 7–10% of all breast cancer deaths, with a 5-year survival rate of 40%. Thus, targeted and effective therapies against IBC are needed. Here, we proposed Lipocalin-2 (LCN2)—a secreted glycoprotein aberrantly abundant in different cancers—as a plausible target for IBC. In immunoblotting, we observed higher LCN2 protein levels in IBC cells than non-IBC cells, where the LCN2 levels were almost undetectable. We assessed the biological effects of targeting LCN2 in IBC cells with small interference RNAs (siRNAs) and small molecule inhibitors. siRNA-mediated LCN2 silencing in IBC cells significantly reduced cell proliferation, viability, migration, and invasion. Furthermore, LCN2 silencing promoted apoptosis and arrested the cell cycle progression in the G0/G1 to S phase transition. We used in silico analysis with a library of 25,000 compounds to identify potential LCN2 inhibitors, and four out of sixteen selected compounds significantly decreased cell proliferation, cell viability, and the AKT phosphorylation levels in SUM149 cells. Moreover, ectopically expressing LCN2 MCF7 cells, treated with two potential LCN2 inhibitors (ZINC00784494 and ZINC00640089) showed a significant decrease in cell proliferation. Our findings suggest LCN2 as a promising target for IBC treatment using siRNA and small molecule inhibitors. MDPI 2021-08-10 /pmc/articles/PMC8395282/ /pubmed/34445288 http://dx.doi.org/10.3390/ijms22168581 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Santiago-Sánchez, Ginette S. Noriega-Rivera, Ricardo Hernández-O’Farrill, Eliud Valiyeva, Fatma Quiñones-Diaz, Blanca Villodre, Emilly S. Debeb, Bisrat G. Rosado-Albacarys, Andrea Vivas-Mejía, Pablo E. Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors |
title | Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors |
title_full | Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors |
title_fullStr | Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors |
title_full_unstemmed | Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors |
title_short | Targeting Lipocalin-2 in Inflammatory Breast Cancer Cells with Small Interference RNA and Small Molecule Inhibitors |
title_sort | targeting lipocalin-2 in inflammatory breast cancer cells with small interference rna and small molecule inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395282/ https://www.ncbi.nlm.nih.gov/pubmed/34445288 http://dx.doi.org/10.3390/ijms22168581 |
work_keys_str_mv | AT santiagosanchezginettes targetinglipocalin2ininflammatorybreastcancercellswithsmallinterferencernaandsmallmoleculeinhibitors AT noriegariveraricardo targetinglipocalin2ininflammatorybreastcancercellswithsmallinterferencernaandsmallmoleculeinhibitors AT hernandezofarrilleliud targetinglipocalin2ininflammatorybreastcancercellswithsmallinterferencernaandsmallmoleculeinhibitors AT valiyevafatma targetinglipocalin2ininflammatorybreastcancercellswithsmallinterferencernaandsmallmoleculeinhibitors AT quinonesdiazblanca targetinglipocalin2ininflammatorybreastcancercellswithsmallinterferencernaandsmallmoleculeinhibitors AT villodreemillys targetinglipocalin2ininflammatorybreastcancercellswithsmallinterferencernaandsmallmoleculeinhibitors AT debebbisratg targetinglipocalin2ininflammatorybreastcancercellswithsmallinterferencernaandsmallmoleculeinhibitors AT rosadoalbacarysandrea targetinglipocalin2ininflammatorybreastcancercellswithsmallinterferencernaandsmallmoleculeinhibitors AT vivasmejiapabloe targetinglipocalin2ininflammatorybreastcancercellswithsmallinterferencernaandsmallmoleculeinhibitors |